IPX 218

Drug Profile

IPX 218

Alternative Names: IPX-218

Latest Information Update: 24 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Impax Pharmaceuticals
  • Class Antiepileptic drugs
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 24 Feb 2016 Discontinued - Phase-II for Epilepsy in USA (unspecified route)
  • 01 Aug 2014 IPX 218 is available for licensing as of 01 Aug 2014. http://www.impaxlabs.com/our_company/future_directions
  • 07 Oct 2013 Phase-II clinical trials in Epilepsy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top